Tracers / [177Lu]Lu-DOTA-r-a-ABA-CPCR4

[177Lu]Lu-DOTA-r-a-ABA-CPCR4

Also written as [Lu-177]DOTA-r-a-ABA-CPCR4
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
—
Syntheses indexed
2
LymphomaPreclinical only, no clinical indication yet

What it is

Compound class
DOTA-conjugated CXCR4-targeting cyclic pentapeptide (CPCR4-based)
Target / mechanism
CXCR4 receptor targeting ligand PMID 32724470
Clinical application
—
Theranostic pair
<a href="/tracers/ga68-dotaraabacpcr4/">ga68-dotaraabacpcr4</a>

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
——————32724470
2020 Theranostics
Manual synthesis————DOTA-r-a-ABA-CPCR432724470
2020 Theranostics
All peptides and their respective natGa-, natLu-, natY- and natBi- complexes were synthesized in analogy to previously published protocols

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-r-a-ABA-CPCR4, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 32724470: 'DOTA-r-a-ABA-CPCR4 (entry 13)'.